Global Hepatitis C Market 2014-2018

世界のC型肝炎治療薬市場(2014-2018)

◆タイトル:Global Hepatitis C Market 2014-2018
◆商品コード:IRTNTR4050
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年9月3日
◆ページ数:104
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Five UserUSD3,300 ⇒換算¥356,400見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、"世界のC型肝炎治療薬市場(2014-2018)"について調査・分析し、エグゼクティブサマリー、市場概観、市場規模及び予測、主要地域別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析等の情報をお届けいたします。

About Hepatitis C
Hepatitis C is a liver disease caused by infection due to hepatitis C virus. Hepatitis C infection predominantly affects the liver; however, other parts of the body are also affected such as the brain and the digestive system. Hepatitis C virus is an RNA virus belonging to the family Flaviviridae and genus hepacivirus. It has a positive-sense, single-stranded RNA molecule enveloped by a lipid bilayer. Hepatitis C can lead to acute infection or chronic infection. Nearly 80 percent of the infected individuals suffering from acute infection are asymptomatic. Symptoms manifested in the rest include nausea, dark urine, fever, anorexia, gray-colored faces, abdominal pain, and joint pain. Nearly 20 percent of infected individuals develop jaundice, which is characterized by the yellowing of skin and eyes. Nearly 15-45 percent of acutely infected individuals recover from the infection spontaneously within the first six months of infection. This happens because the immune system mediated the clearance of the virus from the body. The remaining 55-85 percent of infected individuals who fail to clear the virus within six months develop chronic hepatitis C phase. Chronic infection can lead to mild-to-moderate symptoms or chronic symptoms such as liver fibrosis, liver cirrhosis, and hepatic cancer. The World
Health Organization (WHO) estimates that globally, 130-150 million people suffer from chronic hepatitis B. It also reported that every year 350,000-500,000 infected individuals die because of hepatitis C-related hepatic disorders. Currently, there is no vaccine for the prevention of hepatitis C infection; however, various treatment options for hepatitis C infection are available.

TechNavio’s analysts forecast the Global Hepatitis C market to grow at a CAGR of 19.20 percent over the period 2013-2018.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Hepatitis C market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through sales of various drugs administered to treat chronic hepatitis caused by genotype 1-6 of hepatitis C virus.

TechNavio’s report, the Global Hepatitis C Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Hepatitis C market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions
• Americas
• APAC
• EMEA

Key Vendors
• F. Hoffmann-La Roche
• Gilead Sciences
• Johnson & Johnson
• Merck
• Vertex Pharmaceuticals

Other Prominent Vendors
• Abbvie
• Achillion Pharmaceuticals
• Bristol-Myers Squibb
• Mitsubishi Tanabe Pharma
• Novartis

Market Driver
• Increase in Injection Drug Users
• For a full, detailed list, view our report

Market Challenge
• Side-effects of Current Therapy
• For a full, detailed list, view our report

Market Trend
• Emergence of Interferon-free Therapies
• For a full, detailed list, view our report

Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Mode of Infection Transmission
06.2 Geographical Distribution
06.3 Screening
06.4 Treatment
06.4.1 WHO Guidelines
06.4.2 AASLD guidelines
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Key Marketed Drugs for Treatment of Chronic Hepatitis C
09. Market Segmentation by MOA
09.1 Virus-specific Agents
09.1.1 Polymerase Inhibitors
09.1.2 Protease Inhibitors
09.2 Non-specific Agents
09.2.1 IFN-based Drugs
09.2.2 Others
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.2.1 Roche
18.2.2 Merck
18.2.3 Johnson and Johnson
18.2.4 Vertex Pharmaceuticals
18.2.5 Gilead
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 F. Hoffmann La Roche
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Segmentation by Revenue 2013
19.1.4 Business Segmentation by Revenue 2012 and 2013
19.1.5 Geographical Segmentation by Revenue 2013
19.1.6 Business Strategy
19.1.7 Recent Developments
19.1.8 SWOT Analysis
19.2 Gilead
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Geographical Segmentation by Revenue 2013
19.2.4 Recent Developments
19.2.5 SWOT Analysis
19.3 Johnson & Johnson
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Business Segmentation by Revenue 2013
19.3.4 Business Segmentation by Revenue 2012 and 2013
19.3.5 Geographical Segmentation by Revenue 2013
19.3.6 Business Strategy
19.3.7 Recent Developments
19.3.8 SWOT Analysis
19.4 Merck
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation by Revenue 2013
19.4.4 Business Segmentation by Revenue 2012 and 2013
19.4.5 Sales by Geography
19.4.6 Business Strategy
19.4.7 Key Developments
19.4.8 SWOT Analysis
19.5 Vertex Pharmaceuticals
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Business Segmentation by Revenue 2013
19.5.4 Business Segmentation by Revenue 2012 and 2013
19.5.5 Geographical Segmentation by Revenue 2013
19.5.6 Business Strategy
19.5.7 Recent Developments
19.5.8 SWOT Analysis
20. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Progression of Hepatitis C
Exhibit 3: Risk Factors for Hepatitis C Transmission
Exhibit 4: Prevalence Rates of Hepatitis C Across Different Geographies
Exhibit 5: Prevalence of Hepatitis C Genotypes in Tropical Latin America
Exhibit 6: Key Prevalence Data of Hepatitis C in East Asia and Pacific
Exhibit 7: Prevalence of Hepatitis C Genotypes in East Asia
Exhibit 8: Prevalence of Hepatitis C Genotypes in High Income Asia Pacific
Exhibit 9: Prevalence of Hepatitis C Genotypes in Australasia
Exhibit 10: Key Prevalence Data of Hepatitis C in Europe
Exhibit 11: Prevalence of Hepatitis C Genotypes in Eastern Europe
Exhibit 12: Prevalence of Hepatitis C Genotypes in Western Europe
Exhibit 13: Prevalence of Hepatitis C Genotypes in Central Europe
Exhibit 14: Key Prevalence Data of Hepatitis C in Latin America and Caribbean
Exhibit 15: Prevalence of Hepatitis C Genotypes in Tropical Latin America
Exhibit 16: Prevalence of Hepatitis C Genotypes in Andean Latin America
Exhibit 17: Prevalence of Hepatitis C Genotypes in Central Latin America
Exhibit 18: Prevalence of Hepatitis C Genotypes in South Latin America
Exhibit 19: Key Prevalence Data of Hepatitis C in Middle East and North Africa
Exhibit 20: Prevalence of Hepatitis C Genotypes in North Africa/Middle East
Exhibit 21: Key Prevalence Data of Hepatitis C in North America
Exhibit 22: Prevalence of Hepatitis C Genotypes in High Income Countries in North America
Exhibit 23: Key Prevalence Data of Hepatitis C in South Asia
Exhibit 24: Prevalence of Hepatitis C Genotypes in South Asia
Exhibit 25: Key Prevalence Data of Hepatitis C in Sub-Saharan Africa
Exhibit 26: Prevalence of Hepatitis C Genotypes in Central Sub-Saharan Africa
Exhibit 27: Prevalence of Hepatitis C Genotypes in East Sub-Saharan Africa
Exhibit 28: Prevalence of Hepatitis C Genotypes in South Sub-Saharan Africa
Exhibit 29: Prevalence of Hepatitis C Genotypes in West Sub-Saharan Africa
Exhibit 30: Screening Tests for Hepatitis C Infection
Exhibit 31: Global Hepatitis C Market 2013-2018 (US$ billion)
Exhibit 32: Global Hepatitis C Market Segmentation by MOA
Exhibit 33: Global Hepatitis C Market Segmentation by MOA 2013
Exhibit 34: Global Hepatitis C Market by Geographical Segmentation 2013
Exhibit 35: Geographical Segmentation of Pegasys Revenue 2013
Exhibit 36: Roche: Pipeline Candidates for Hepatitis C
Exhibit 37: Victrelis’ Revenue 2011-2013 (US$ million)
Exhibit 38: Merck: Pipeline Candidates for Hepatitis C
Exhibit 39: Johnson & Johnson : Incivo’s Revenue 2011-2013 (US$ million)
Exhibit 40: Olysio’s Revenue 2014 (US$ million)
Exhibit 41: Vertex Pharmaceuticals: Incivek’s Revenue 2011-2013 (US$ million)
Exhibit 42: Vertex: Pipeline Candidates for Hepatitis C
Exhibit 43: Gilead: Pipeline Candidates for Hepatitis C
Exhibit 44: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 45: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 46: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Pharmaceuticals Division)
Exhibit 47: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Diagnostics Division)
Exhibit 48: Gilead: Geographical Segmentation by Revenue 2013
Exhibit 49: Johnson & Johnson: Business Segmentation by Revenue 2013
Exhibit 50: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 51: Johnson & Johnson: Geographical Segmentation by Revenue 2013
Exhibit 52: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 53: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 54: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 55: Vertex Pharmaceuticals: Business Segmentation by Revenue 2013
Exhibit 56: Vertex Pharmaceuticals: Business Segmentation by Revenue 2012 and 2013 (US$ million)



【掲載企業】

F. Hoffmann-La Roche, Gilead Sciences, Johnson & Johnson, Merck, Vertex Pharmaceuticals, Abbvie, Achillion Pharmaceuticals, Bristol-Myers Squibb, Mitsubishi Tanabe Pharma, Novartis

【資料のキーワード】

C型肝炎治療、製薬、慢性肝炎

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[世界のC型肝炎治療薬市場(2014-2018)]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆